[The effect of the calciumantagonist dimeditiapramine on thallium-201 myocardial perfusion during exercise in patients with coronary heart disease (author's transl)].
The effect of dimeditiapramine (Ro 11-1781), a new calciumantagonist, on thallium-201 myocardial perfusion during exercise was studied in a double-blind trial with 10 patients suffering from coronary heart disease. Treatment with a single intravenous dose of 1 mg/kg body weight resulted in a significant regional thallium-201 perfusion increase in 8 out of 10 patients. These results correspond with the clinically observed decrease in exercise-induced angina and ischaemic ECG alterations. The findings indicate that dimeditiapramine might be a useful anti-anginal drug.
D000368:Aged; D002118:Calcium / Q000037:antagonists & inhibitors; D003327:Coronary Disease / Q000188:drug therapy*; D003331:Coronary Vessels / Q000187:drug effects; D006321:Heart / Q000000981:diagnostic imaging / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011437:Propylamines / Q000627:therapeutic use*; D011868:Radioisotopes; D011877:Radionuclide Imaging; D013793:Thallium; D013976:Tiapamil Hydrochloride
D011437:Propylamines; D011868:Radioisotopes; D013793:Thallium; D002118:Calcium; D013976:Tiapamil Hydrochloride
Beeinflussung der Thallium-201-Myokardperfusion unter Belastung bei Patienten mit koronarer Herzkrankheit durch den Kalziumantagonisten Dimeditiapramin (Ro-11-1781).